{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:40:24Z","timestamp":1793835624535,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403761"],"award-info":[{"award-number":["82403761"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctor research grant of Sichuan University","award":["2023SCU12047"],"award-info":[{"award-number":["2023SCU12047"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04240-9","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T03:10:34Z","timestamp":1745982634000},"page":"186-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study"],"prefix":"10.1007","volume":"89","author":[{"given":"Ziliang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The MDT of Advanced Thyroid Cancer of West China Hospital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"5","key":"4240_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"L. Boucai, M. Zafereo, M.E. Cabanillas, Thyroid cancer: a review. JAMA 331(5), 425\u2013435 (2024). https:\/\/doi.org\/10.1001\/jama.2023.26348","journal-title":"JAMA"},{"issue":"11","key":"4240_CR2","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/jcem.84.11.6115","volume":"84","author":"Y Kitamura","year":"1999","unstructured":"Y. Kitamura, K. Shimizu, M. Nagahama, K. Sugino, O. Ozaki, T. Mimura et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J. Clin. Endocrinol. Metab. 84(11), 4043\u20134049 (1999). https:\/\/doi.org\/10.1210\/jcem.84.11.6115","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"4240_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/00005537-200106000-00011","volume":"111","author":"NJP Beasley","year":"2001","unstructured":"N.J.P. Beasley, P.G. Walfish, I. Witterick, J.L. Freeman, Cause of death in patients with well-differentiated thyroid carcinoma. Laryngoscope 111(6), 989\u2013991 (2001). https:\/\/doi.org\/10.1097\/00005537-200106000-00011","journal-title":"Laryngoscope"},{"issue":"6","key":"4240_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40618-022-01966-5","volume":"46","author":"M Abuduwaili","year":"2023","unstructured":"M. Abuduwaili, A. Su, Z. Xing, B. Xia, Z. Wu, Y. Fei et al. Clinical significance of extrathyroidal extension to major vessels in papillary thyroid carcinoma. J. Endocrinol. Invest. 46(6), 1155\u20131167 (2023). https:\/\/doi.org\/10.1007\/s40618-022-01966-5","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"4240_CR5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.surg.2016.04.027","volume":"160","author":"LY Wang","year":"2016","unstructured":"L.Y. Wang, I.J. Nixon, S.G. Patel, F.L. Palmer, R.M. Tuttle, A. Shaha et al. Operative management of locally advanced, differentiated thyroid cancer. Surgery 160(3), 738\u2013746 (2016). https:\/\/doi.org\/10.1016\/j.surg.2016.04.027","journal-title":"Surgery"},{"key":"4240_CR6","doi-asserted-by":"publisher","first-page":"e389708","DOI":"10.1200\/EDBK_389708","volume":"43","author":"S Agosto Salgado","year":"2023","unstructured":"S. Agosto Salgado, E.R. Kaye, Z. Sargi, C.H. Chung, M. Papaleontiou, Management of advanced thyroid cancer: overview, advances, and opportunities. Am. Soc. Clin. Oncol. Educ. Book. 43, e389708 (2023). https:\/\/doi.org\/10.1200\/EDBK_389708","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"2","key":"4240_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000494880","volume":"8","author":"KE Stewart","year":"2019","unstructured":"K.E. Stewart, M.W.J. Strachan, D. Srinivasan, M. MacNeill, L. Wall, I.J. Nixon, Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur. Thyroid. J. 8(2), 102\u2013107 (2019). https:\/\/doi.org\/10.1159\/000494880","journal-title":"Eur. Thyroid. J."},{"issue":"23","key":"4240_CR8","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1200\/jco.2009.27.4225","volume":"28","author":"JM Cleary","year":"2010","unstructured":"J.M. Cleary, P.M. Sadow, G.W. Randolph, E.L. Palmer, T.P. Lynch, Y.E. Nikiforov et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J. Clin. Oncol. 28(23), e390\u2013392 (2010). https:\/\/doi.org\/10.1200\/jco.2009.27.4225","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"4240_CR9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"J.R. Wang, M.E. Zafereo, R. Dadu, R. Ferrarotto, N.L. Busaidy, C. Lu et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-Mutated anaplastic thyroid carcinoma. Thyroid 29(8), 1036\u20131043 (2019). https:\/\/doi.org\/10.1089\/thy.2019.0133","journal-title":"Thyroid"},{"key":"4240_CR10","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"E. Driehuis, K. Kretzschmar, H. Clevers, Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380\u20133409 (2020). https:\/\/doi.org\/10.1038\/s41596-020-0379-4","journal-title":"Nat. Protoc."},{"issue":"8","key":"4240_CR11","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.7150\/thno.96027","volume":"14","author":"D Xiang","year":"2024","unstructured":"D. Xiang, A. He, R. Zhou, Y. Wang, X. Xiao, T. Gong et al. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics 14(8), 3300\u20133316 (2024). https:\/\/doi.org\/10.7150\/thno.96027","journal-title":"Theranostics"},{"issue":"7","key":"4240_CR12","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"L. Thorel, M. Perr\u00e9ard, R. Florent, J. Divoux, S. Coffy, A. Vincent et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp. Mol. Med. 56(7), 1531\u20131551 (2024). https:\/\/doi.org\/10.1038\/s12276-024-01272-5","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"4240_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","volume":"21","author":"J Kim","year":"2020","unstructured":"J. Kim, B.-K. Koo, J.A. Knoblich, Human organoids: model systems for human biology and medicine. Nat. Rev. Mol. Cell Biol. 21(10), 571\u2013584 (2020). https:\/\/doi.org\/10.1038\/s41580-020-0259-3","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"4240_CR14","doi-asserted-by":"publisher","unstructured":"A. Boil\u00e8ve, J. Cartry, N. Goudarzi, S. Bedja, J.R.R. Mathieu, M.A. Bani et al. Organoids for functional precision medicine in advanced pancreatic cancer. Gastroenterology. (2024). https:\/\/doi.org\/10.1053\/j.gastro.2024.05.032","DOI":"10.1053\/j.gastro.2024.05.032"},{"issue":"1","key":"4240_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0379-410.1038\/s41467-021-22676-1","volume":"12","author":"Y Hu","year":"2021","unstructured":"Y. Hu, X. Sui, F. Song, Y. Li, K. Li, Z. Chen et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat. Commun. 12(1), 2581 (2021). https:\/\/doi.org\/10.1038\/s41596-020-0379-410.1038\/s41467-021-22676-1","journal-title":"Nat. Commun."},{"issue":"4","key":"4240_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ijc.34945","volume":"155","author":"Y-y Lin","year":"2024","unstructured":"Y.-y Lin, H.-f Gao, H. Li, Q. Hu, B.-l Du, S. Li et al. Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer. Int. J. Cancer 155(4), 697\u2013709 (2024). https:\/\/doi.org\/10.1002\/ijc.34945","journal-title":"Int. J. Cancer"},{"issue":"7","key":"4240_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101650","volume":"5","author":"A Vistoso Monreal","year":"2024","unstructured":"A. Vistoso Monreal, H. Zhao, P.P. Sedghizadeh, D.C. Lin, Patient-derived tumor organoids to model drug response in gastric cancer. Cell Rep. Med. 5(7), 101650 (2024). https:\/\/doi.org\/10.1016\/j.xcrm.2024.101650","journal-title":"Cell Rep. Med."},{"issue":"1","key":"4240_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13046-024-02980-6","volume":"43","author":"LP Smabers","year":"2024","unstructured":"L.P. Smabers, E. Wensink, C.S. Verissimo, E. Koedoot, K.-C. Pitsa, M.A. Huismans et al. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response. J. Exp. Clin. Cancer Res. 43(1), 61 (2024). https:\/\/doi.org\/10.1186\/s13046-024-02980-6","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"4240_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13046-023-02683-4","volume":"42","author":"LH Jensen","year":"2023","unstructured":"L.H. Jensen, S.R. Rogatto, J. Lindebjerg, B. Havelund, C. Abildgaard, L.M. do Canto et al. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study. J. Exp. Clin. Cancer Res. 42(1), 115 (2023). https:\/\/doi.org\/10.1186\/s13046-023-02683-4","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"4240_CR20","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1210\/clinem\/dgab020","volume":"106","author":"D Chen","year":"2021","unstructured":"D. Chen, Y. Tan, Z. Li, W. Li, L. Yu, W. Chen et al. Organoid cultures derived from patients with papillary thyroid cancer. J. Clin. Endocrinol. Metab. 106(5), 1410\u20131426 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4240_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03848-z","volume":"21","author":"D Chen","year":"2023","unstructured":"D. Chen, X. Su, L. Zhu, H. Jia, B. Han, H. Chen et al. Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. J. Transl. Med. 21(1), 9 (2023). https:\/\/doi.org\/10.1186\/s12967-022-03848-z","journal-title":"J. Transl. Med."},{"issue":"1","key":"4240_CR22","doi-asserted-by":"publisher","first-page":"bqae162","DOI":"10.1210\/endocr\/bqae162","volume":"166","author":"X Zhang","year":"2024","unstructured":"X. Zhang, J. Liu, Y. Ni, Y. Yang, T. Tian, X. Zheng et al. Modeling clinical radioiodine uptake by using organoids derived from differentiated thyroid cancer. Endocrinology 166(1), bqae162 (2024). https:\/\/doi.org\/10.1210\/endocr\/bqae162","journal-title":"Endocrinology"},{"issue":"1","key":"4240_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"R. Lencioni, J.M. Llovet, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30(1), 52\u201360 (2010). https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin. Liver Dis."},{"issue":"9940","key":"4240_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940), 319\u2013328 (2014). https:\/\/doi.org\/10.1016\/s0140-6736(14)60421-9","journal-title":"Lancet"},{"issue":"21","key":"4240_CR25","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.Ccr-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"R.L. Camp, M. Dolled-Filhart, D.L. Rimm, X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10(21), 7252\u20137259 (2004). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-0713","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"4240_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","volume":"8","author":"Y Lin","year":"2022","unstructured":"Y. Lin, S. Qin, Z. Li, H. Yang, W. Fu, S. Li et al. Apatinib vs Placebo in patients with locally advanced or metastatic, radioactive iodine\u2013refractory differentiated thyroid cancer: the REALITY randomized clinical trial. JAMA Oncol. 8(2), 242\u2013250 (2022). https:\/\/doi.org\/10.1001\/jamaoncol.2021.6268","journal-title":"JAMA Oncol."},{"issue":"7","key":"4240_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621\u2013630 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"4240_CR28","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1089\/thy.2021.0307","volume":"31","author":"NS Huang","year":"2021","unstructured":"N.S. Huang, W.J. Wei, J. Xiang, J.Y. Chen, Q. Guan, Z.W. Lu et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase II clinical trial. Thyroid 31(12), 1808\u20131813 (2021). https:\/\/doi.org\/10.1089\/thy.2021.0307","journal-title":"Thyroid"},{"issue":"7","key":"4240_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1089\/thy.2024.0090","volume":"34","author":"F Pitoia","year":"2024","unstructured":"F. Pitoia, E. Abelleira, A. Rom\u00e1n-Gonz\u00e1lez, D.L.S. Danilovic, R.S. Scheffel, A.L. Maia et al. Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary latin american experience. Thyroid 34(7), 949\u2013952 (2024). https:\/\/doi.org\/10.1089\/thy.2024.0090","journal-title":"Thyroid"},{"issue":"1","key":"4240_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35431-x","volume":"14","author":"S Li","year":"2023","unstructured":"S. Li, W. Yu, F. Xie, H. Luo, Z. Liu, W. Lv et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat. Commun. 14(1), 8 (2023). https:\/\/doi.org\/10.1038\/s41467-022-35431-x","journal-title":"Nat. Commun."},{"issue":"5","key":"4240_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"C. Springfeld, C.R. Ferrone, M.H.G. Katz, P.A. Philip, T.S. Hong, T. Hackert et al. Neoadjuvant therapy for pancreatic cancer. Nat. Rev. Clin. Oncol. 20(5), 318\u2013337 (2023). https:\/\/doi.org\/10.1038\/s41571-023-00746-1","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"36","key":"4240_CR32","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1200\/jco.2005.07.740","volume":"23","author":"SR Alberts","year":"2005","unstructured":"S.R. Alberts, W.L. Horvath, W.C. Sternfeld, R.M. Goldberg, M.R. Mahoney, S.R. Dakhil et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J. Clin. Oncol. 23(36), 9243\u20139249 (2005). https:\/\/doi.org\/10.1200\/jco.2005.07.740","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"4240_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/jco.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"T. Andr\u00e9, D. Tougeron, G. Piessen, C. de la Fouchardi\u00e8re, C. Louvet, A. Adenis et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J. Clin. Oncol. 41(2), 255\u2013265 (2023). https:\/\/doi.org\/10.1200\/jco.22.00686","journal-title":"J. Clin. Oncol."},{"issue":"6378","key":"4240_CR34","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"G. Vlachogiannis, S. Hedayat, A. Vatsiou, Y. Jamin, J. Fern\u00e1ndez-Mateos, K. Khan et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359(6378), 920\u2013926 (2018). https:\/\/doi.org\/10.1126\/science.aao2774","journal-title":"Science"},{"issue":"7","key":"4240_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101627","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Y. Zhao, S. Li, L. Zhu, M. Huang, Y. Xie, X. Song et al. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Cell Rep. Med. 5(7), 101627 (2024). https:\/\/doi.org\/10.1016\/j.xcrm.2024.101627","journal-title":"Cell Rep. Med."},{"issue":"1","key":"4240_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Y. Yao, X. Xu, L. Yang, J. Zhu, J. Wan, L. Shen et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26(1), 17\u201326.e16 (2020). https:\/\/doi.org\/10.1016\/j.stem.2019.10.010","journal-title":"Cell Stem Cell"},{"issue":"6","key":"4240_CR37","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jamaoncol.2015.6315","volume":"2","author":"GR Oxnard","year":"2016","unstructured":"G.R. Oxnard, K.H. Wilcox, M. Gonen, M. Polotsky, B.R. Hirsch, L.H. Schwartz, Response rate as a regulatory end point in single-arm studies of advanced solid tumors. JAMA Oncol. 2(6), 772\u2013779 (2016). https:\/\/doi.org\/10.1001\/jamaoncol.2015.6315","journal-title":"JAMA Oncol."},{"issue":"6","key":"4240_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/thy.2017.0102","volume":"27","author":"RM Tuttle","year":"2017","unstructured":"R.M. Tuttle, B. Haugen, N.D. Perrier, Updated american joint committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth Edition): what changed and why? Thyroid\u00ae 27(6), 751\u2013756 (2017). https:\/\/doi.org\/10.1089\/thy.2017.0102","journal-title":"Thyroid\u00ae"},{"issue":"10298","key":"4240_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0140-6736(21)00766-2","volume":"398","author":"JG Moss","year":"2021","unstructured":"J.G. Moss, O. Wu, A.R. Bodenham, R. Agarwal, T.F. Menne, B.L. Jones et al. Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet 398(10298), 403\u2013415 (2021). https:\/\/doi.org\/10.1016\/s0140-6736(21)00766-2","journal-title":"Lancet"},{"key":"4240_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100961","volume":"47","author":"J Ji","year":"2024","unstructured":"J. Ji, T. Liu, Y. Yao, W. Liu, H. Ning, T. Wang et al. Characteristics and survival of primary urothelial carcinoma of the prostate: a multi-center retrospective study of 18 cases. Neoplasia 47, 100961 (2024). https:\/\/doi.org\/10.1016\/j.neo.2023.100961","journal-title":"Neoplasia"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04240-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04240-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04240-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:49:38Z","timestamp":1751597378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04240-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4240"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04240-9","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the Institutional Review Board and Ethics Committee of West China Hospital (No. 20221642) and was conducted in compliance with the Helsinki Declaration. The trial was registered at ClinicalTrials.gov (NCT06482086).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants or their legal representatives before the trial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors confirm that informed consent for the publication of the information regarding Patient A and Patient B in the results section in this manuscript was obtained from the human research participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}